In 2025, BeOne Medicines completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
BeOne Medicines has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 11,539a | 3,547a | 2,462a | |
Total Scope 2 | ||||
Market-Based | 102,622a | 89,591a | 76,465a | |
Location-Based | 90,661a | 81,095a | 76,485a | |
Unspecified Calculation Method | N/A | N/A | N/A | |
Total Scope 3 | 627,386a | 650,594a | 469,139a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 2.1596a | 0.9309a | 1.0013a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of BeOne Medicines amounted to 102,200 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of BeOne Medicines increased by 20.74%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of BeOne Medicines were 11,539 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, BeOne Medicines's Scope 1 emissions have increased by 2,056.82%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2024), BeOne Medicines's Scope 1 emissions increased by 225.32%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, BeOne Medicines reported Scope 2 greenhouse gas (GHG) emissions of 102,622 tCO₂e using the market-based method and 90,661 tCO₂e using the location-based method.a
Compared to the previous year (2024), BeOne Medicines's Scope 2 emissions (Location-Based) rose by 11.8% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, BeOne Medicines reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, BeOne Medicines reported 627,386 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of BeOne Medicines includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, BeOne Medicines reported total Scope 3 emissions of 627,386 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.88% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.12% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2024), BeOne Medicines's Scope 3 emissions remained relatively stable, indicating that BeOne Medicines's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, BeOne Medicines reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2025, the largest contributors to BeOne Medicines's Scope 3 emissions were:a
In 2025, BeOne Medicines reported Scope 1 greenhouse gas (GHG) emissions of 11,539 tCO₂e and total revenues of USD 5,343 millions. This translates into an emissions intensity of 2.16 tCO₂e per millions USD.a
In 2025, BeOne Medicines reported a Scope 1 emissions intensity of 2.16 tCO₂e per millions USD. Compared to the peer group median of 2.44, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, BeOne Medicines ranked 11 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
BeOne Medicines is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, BeOne Medicines reported a total carbon footprint of 729,586 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 0.77% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to BeOne Medicines's total carbon footprint was Scope 3 emissions, accounting for 85.99% of the company's total carbon footprint, followed by Scope 2 emissions at 12.43%.a